Valbiotis Reports Strong 2025 Revenue Growth Amid Strategic Shift
La Rochelle, France – Valbiotis SA (FR0013254851 – ALVAL, PEA / PME eligible) announced its 2025 financial results, revealing a five-fold increase in revenue despite a limited product portfolio for much of the year. The company is undergoing a strategic transformation, shifting focus from research and development to commercialization and international expansion.
Revenue Surge Driven by Late-Year Momentum
Valbiotis reported revenue of €905,000 for 2025, a significant jump from €175,000 in 2024 Sharewise. The fourth quarter of 2025 alone generated €400,000 in sales, representing a 2.3x acceleration compared to the third quarter. Key operational indicators also showed improvement, with a pharmacy restocking rate reaching 65% and the average value of business-to-business (B2B) orders increasing by 198% to €471. E-commerce sales saw a 325% increase in customers, reaching 4,030, with an average basket size of €85.8 and a 70% recommendation rate.
Strategic Reprioritization: R&D Cuts, Marketing Boost
The revenue growth occurred alongside a significant restructuring of operational costs. Valbiotis reduced its research and development (R&D) expenses by 80%, from €4,638,000 in 2024 to €921,000 in 2025 FinanzWire. This reduction is attributed to the completion of major clinical studies and the closure of the Riom research laboratory. Concurrently, sales and marketing expenses increased by 18% to €5,140,000, now representing 50% of operational expenses (excluding stock-based compensation), up from 30% the previous year. General expenses were also reduced by 32% to €2,096,000 through structural savings implemented in the second half of 2024. Overall operational expenses decreased by 30% to €10,540,000.
Financial Position and International Expansion
As of December 31, 2025, Valbiotis held €8,676,000 in cash, down from €11,580,000 a year earlier FinanzWire. Cash consumption was €2,904,000 for the year, offset by a €5,699,000 fundraising round in June 2025. The company’s cash flow improved to -€8,038,000 compared to -€11,537,000 in 2024, thanks to cost savings. This provides a cash runway until the end of 2026 without requiring additional financing.
Valbiotis has also established key international partnerships, including a 49% joint venture in Asia (China, Hong Kong, Vietnam, Indonesia, Japan, Taiwan, Singapore) signed in November 2025, and an exclusive distribution agreement in the Middle East finalized in January 2026 Valbiotis Investor Relations. These agreements are expected to generate revenue in 2026. In France, the company’s distribution network includes 474 direct pharmacies and partnerships with 15 pharmaceutical groups, providing access to 3,000 member pharmacies.
Outlook for 2026 and Beyond
Looking ahead, Valbiotis anticipates continued commercial acceleration in France and the contribution of revenue from its new international partnerships in 2026. The company has reaffirmed its financial goals, targeting turnover exceeding €25 million and positive EBITDA in France by 2027, and exceeding €100 million in turnover with an EBITDA margin of 25-30% by 2030 Valbiotis Investor Relations.